Menstrual pain relief IUD created in collaboration by Meliodays Medical and Celanese, free of hormones
In the ongoing quest to improve women's health, a groundbreaking collaboration between Meliodays Medical and Celanese Corporation is set to revolutionize the treatment of menstrual pain. The product in question, MelioOne, is a hormone-free, non-contraceptive intrauterine device (IUD) designed specifically for localized relief of menstrual pain, currently in pre-clinical development.
The partnership, signed around July 2025, brings together Meliodays' innovative medical device design and Celanese's VitalDose Drug Delivery Platform, a technology renowned for its reliable, controlled drug delivery. This platform has been used in approved drug products in the US and Europe for over two decades, providing a strong foundation for MelioOne's design.
MelioOne resembles a standard hormonal IUD in shape and insertion method but differs significantly in its hormone-free formulation and pain-relief purpose. The device leverages the VitalDose platform to control the release of a non-hormonal active pharmaceutical ingredient (API), targeting the source of pain and avoiding systemic side effects commonly associated with oral pain medications.
As MelioOne progresses through pre-clinical development, the next steps will logically involve clinical trials to assess safety and efficacy, followed by regulatory approval processes. The collaboration suggests ongoing material science and pharmaceutical formulation work to optimize the delivery and effectiveness of the pain-relief agent.
Celanese Corporation, a large chemical company with diverse operations, is leading the way in drug delivery technology with the VitalDose platform. Although the company's overall financial outlook for 2025 includes some revenue and earnings challenges unrelated to MelioOne, their expertise in drug delivery underpins their role in this healthcare innovation.
Simone Sabbione, CEO and co-founder of Meliodays, stated that the partnership with Celanese is a significant step towards revolutionizing the treatment of menstrual pain. With more than 80% of menstruating people experiencing period pain and cramps, the need for an effective treatment without the need for hormones or systemic painkillers is paramount.
If successful, MelioOne is anticipated to be prescribed by healthcare professionals to relieve women of menstrual pain. Celanese remains optimistic about the potential impact of MelioOne, with the VitalDose Drug Delivery Platform set to continue advancing in therapies for women and anywhere where sustained drug delivery offers benefits.
[1] Meliodays Medical Press Release, July 2025 [2] Celanese Corporation Press Release, July 2025 [3] Clinical Trials Arena, July 2025 [4] FiercePharma, July 2025 [5] Chemical & Engineering News, July 2025
- This collaboration between Meliodays Medical and Celanese Corporation, as mentioned in the Meliodays Medical Press Release from July 2025, aims to revolutionize the treatment of menstrual pain through the development of MelioOne, a hormone-free IUD designed specifically for health-and-wellness, particularly focusing on womens-health.
- As the technology in health-and-wellness, specifically womens-health, advances, Celanese Corporation's VitalDose Drug Delivery Platform, a technology renowned for its reliable, controlled drug delivery, may potentially have significant impacts beyond MelioOne, as stated in the Celanese Corporation Press Release from July 2025.
